Your browser doesn't support javascript.
loading
Management of Diabetic Macular Edema: Guidelines from the Emirates Society of Ophthalmology.
Al Qassimi, Noura; Kozak, Igor; Al Karam, Maysoon; Neri, Piergiorgio; Aduriz-Lorenzo, Patricio M; Attawan, Alaa; Awadalla, Mohamed; El Khashab, Ahmed; Abdul-Nabi, Mohamed; Safar, Ammar; Al Shamsi, Hanan; Rao, Prasan; Rao, Madhav; Farid, Amr; Gurbaxani, Avinash.
Afiliação
  • Al Qassimi N; Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates. n.alqassimi@gmail.com.
  • Kozak I; Moorfields Eye Hospital, Abu Dhabi, United Arab Emirates.
  • Al Karam M; YAS Clinic, Abu Dhabi, United Arab Emirates.
  • Neri P; Cleveland Clinic, Abu Dhabi, United Arab Emirates.
  • Aduriz-Lorenzo PM; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.
  • Attawan A; Khalifa University, Abu Dhabi, United Arab Emirates.
  • Awadalla M; Dubai Hospital, Dubai, United Arab Emirates.
  • El Khashab A; Tawam Hospital, Al Ain, United Arab Emirates.
  • Abdul-Nabi M; Al Qassimi Hospital, Sharjah, United Arab Emirates.
  • Safar A; Eye Consultants Center Dubai, Dubai, United Arab Emirates.
  • Al Shamsi H; Sheikh Shakhbout Medical City in Association With Mayo Clinic, Abu Dhabi, United Arab Emirates.
  • Rao P; Moorfields Eye Hospital, Dubai, United Arab Emirates.
  • Rao M; Tawam Hospital, Al Ain, United Arab Emirates.
  • Farid A; Medcare Eye Centre, Dubai, United Arab Emirates.
  • Gurbaxani A; Burjeel Hospital, Abu Dhabi, United Arab Emirates.
Ophthalmol Ther ; 11(5): 1937-1950, 2022 Oct.
Article em En | MEDLINE | ID: mdl-35896888
In the United Arab Emirates, retinopathy has been shown to be present in 19% of the diabetic population, with diabetes identified in up to 40% of individuals aged over 55 years. Despite the prevalence of diabetic retinal diseases, there are no unified national guidelines on the management of diabetic macular edema (DME). These published guidelines are based on evidence taken from the literature and published trials of therapies, and consensus opinion of a representative expert panel with an interest in this condition, convened by the Emirates Society of Ophthalmology. The aim is to provide evidence-based, clinical guidance for the best management of different aspects of DME, with a special focus on vision-threatening diabetic retinopathy. Treatment should be initiated in patients with best-corrected visual acuity 20/30 or worse, and/or features of DME as seen on optical coherence tomography (OCT) with central retinal thickness (CRT) of at least 300 µm or in symptomatic patients with vision better than 20/25, and/or CRT less than 300 µm where there are OCT features consistent with center-involving macular edema. The treatment of DME is effective irrespective of glycated hemoglobin (HbA1c) level, and treatment must not be denied or delayed in order to optimize systemic parameters. All ophthalmic treatment options should be discussed with the patient for better compliance and expectations. Non-center-involving DME can be initially observed until progression toward the center is documented. Macular laser no longer has a primary role in center-involving DME, and anti-vascular endothelial growth factor (anti-VEGF) therapy should be considered as first-line treatment for all patients, unless contraindicated. If anti-VEGF is contraindicated, a steroid dexamethasone implant can be considered for first-line treatment. Recommendations for the treatment of DME in special circumstances and in relapsing and refractory DME are also discussed.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article